Search

for
Search:

GlossaryOzempic

Ozempic is a medication primarily used to manage type 2 diabetes by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Its relevance to hair loss stems from anecdotal reports and emerging studies suggesting that weight loss associated with Ozempic may lead to temporary hair shedding in some individuals. Key distinguishing characteristics include its active ingredient, semaglutide, and its mechanism of action, which involves appetite suppression and increased insulin sensitivity. While not directly a hair loss treatment, its side effects can impact hair health in certain users.

Related Terms

Sort by

Research

30 / 1000+ results

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations , August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

research Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs

29 citations , September 2023 in “Journal of Clinical Medicine”

Semaglutide helps obese PCOS patients lose weight and improve health.

research Alopecia and Semaglutide: Connecting the Dots for Patient Safety

4 citations , March 2025 in “Journal of Cosmetic Dermatology”

Semaglutide may cause hair loss, but more research is needed to confirm this.

research Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions

1 citations , September 2025 in “Medicina Moderna - Modern Medicine”

Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.

research Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report

January 2026 in “Cureus”

A rash from semaglutide may be due to propylene glycol, not the drug itself.

research Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review

October 2025 in “Brazilian Journal of Hair Health”

Hair loss from weight-loss treatments is usually temporary and reversible.

research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review

February 2025 in “Skin Appendage Disorders”

GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.

Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database

November 2024 in “Circulation”

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

research 53028 Semaglutide and Hair Loss: A Real-World Analysis

September 2024 in “Journal of the American Academy of Dermatology”

Semaglutide does not significantly increase the risk of hair loss.

GLP-1 Receptor Agonists and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions

research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions

June 2025

GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.

research Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus

2 citations , January 2025 in “Cutis”

Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.

research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons

1 citations , September 2025 in “Dermatology and Therapy”

GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.

Endocrinology and Aesthetic Medicine Edition X

research Endocrinologia e Medicina Estética Ed. X

February 2026 in “Editora Pasteur eBooks”

research Semaglutide and the Skin: An Overview of Current Evidence

January 2026 in “Quality in Sport”

Semaglutide may help some skin disorders but can also cause skin issues.

Ayurveda and Bioactives as Adjuvant for DNA Modulation in Cancer Treatment and Adverse Drug Reaction – A Glimpse of Traditional Indian Nanotechnology

research Ayurveda & Bioactives as Adjuvant for Dna Modulation in Cancer Treatment & Adverse Drug Reaction [ADR] – A Glimpse of Traditional Indian Nanotechnology

March 2024 in “Qeios”

Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.

Efficacy and Safety of Ozenoxacin 1% Cream for Topical Treatment of Impetigo in Children and Adults

research Efficacy and safety of ozenoxacin 1% cream, a novel antibiotic for the topical treatment of impetigo in children and adults

August 2018 in “Journal of The American Academy of Dermatology”

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

research Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes

6 citations , August 2024 in “The Journal of Dermatology”

Ozenoxacin reduces sebum production, helping manage acne.

Novelty or Prudence? The Delicate Balance in Pharmacological Updates

research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica

October 2025 in “Actualización en Medicina de Familia”

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

research PIOGLITAZONE: A NEW PARADIGM IN MANAGEMENT OF PCOS; AN OPEN LABELLED STUDY

July 2020 in “Zenodo (CERN European Organization for Nuclear Research)”

Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.

research Clobetasol/minoxidil

February 2023 in “Reactions Weekly”

research Management of adolescent polycystic ovary syndrome

August 2025 in “Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh”

SPIOMET therapy may be a promising alternative to oral contraceptives for treating adolescent PCOS.

research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.

33 citations , May 2017 in “Journal of Clinical Oncology”

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

research Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies

January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)”

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

research Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome

26 citations , January 2016 in “Indian journal of endocrinology and metabolism”

Both metformin and pioglitazone improve PCOS symptoms, but pioglitazone is a good alternative for those who can't take metformin.

research Unexpected hypozincaemia in a patient with discharging empyema that proved resistant to replacement therapy

2 citations , March 2013 in “BMJ Case Reports”

Zinc levels remained low despite treatment, likely due to absorption issues.

research Dipyridamole-Associated Shock and Pulmonary Edema; Oxcarbazepine-Induced Resistant Ventricular Fibrillation; Finasteride-Induced Pseudoporphyria; Suicidal Ideation Associated with Asenapine; Rediscovering Adverse Anticholinergic Effects; Prevalence of Adverse Drug Events in Ambulatory Care

1 citations , October 2011 in “Hospital Pharmacy”

research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

9 citations , July 2022 in “Journal of Clinical Oncology”

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

research peri ‐Xanthenoxanthene (PXX): a Versatile Organic Photocatalyst in Organic Synthesis

11 citations , April 2021 in “Advanced synthesis & catalysis”

PXX is an effective and affordable photocatalyst for creating new chemical bonds in organic synthesis.

research Fabrication of Novel Omeprazole-Based Chitosan Coated Nanoemulgel Formulation for Potential Anti-Microbia; In Vitro and Ex Vivo Characterizations

8 citations , March 2023 in “Polymers”

The new omeprazole nanoemulgel shows promise as a topical treatment for infections.

research The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy

1 citations , January 2022 in “Journal of Cancer Therapy”

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.